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Introduction: The drug treatment of autism spectrum disorders is often poorly tolerated and has traditionally
targeted associated conditions (such as inattention or irritability) that frequently coexist, with limited benefit for the
core social deficits. Here, I describe the novel use of a low dose of the anti-epileptic phenytoin to enhance social
functioning in a patient with an autism spectrum disorder.
Case presentation: I present the case of a 19-year-old Caucasian man with autism spectrum disorder treated with
stimulant medication since early childhood. He experienced long-standing difficulties in establishing and maintaining
relationships and reading social cues, and was socially isolated. Within 10 minutes of a single sublingual low dose of
phenytoin there was an immediate observable improvement in his eye contact and integration of both verbal and
non-verbal communication. This enhanced social functioning associated with his adherence to the low-dose phenytoin
therapy was maintained for over 18 months of follow-up. These clinical observations were supported by ratings using
the Autism-Spectrum Quotient and the Depression, Anxiety and Stress Scales, recorded pre-treatment and after seven
months on 5mg phenytoin.
Conclusion: This case report provides the first potential evidence that a low dose of phenytoin, a widely used and well
tolerated anti-epileptic medication, may be capable of modifying the core social cognitive deficits associated with
autism spectrum disorders. While acknowledging this is a single case study, the lack of availability of safe and effective
treatments to address the important core deficits associated with autism spectrum disorders makes this case
noteworthy.
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Autism is a neurodevelopmental disorder characterized
by dysfunction in three core behavioral dimensions:
repetitive behaviors, social deficits and language abnor-
malities. Autism is assigned to a spectrum of disorders
that are referred to as autism spectrum disorders
(ASDs), distinguishable in the severity of symptoms [1].
Autism is the model disorder of social dysfunction - a
key inability to respond appropriately to social cues, in-
cluding failure to accurately interpret facial expressions
[2]. Additional social deficits include unusual eye contact,
limitations in facial expression directed to other people,
atypical social engagement and responsiveness, difficulty
with peer relationships, lack of awareness of other people’s
thoughts and feelings, poor communication skills, andCorrespondence: philb@gosforthclinic.com.au
PO Box 680, Maroochydore 4558, QLD, Australia
© 2015 Bird; licensee BioMed Central. This is a
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.difficulty initiating social contacts through verbal or non-
verbal means [3].
Only two medications, risperidone and aripiprazole,
have so far been approved by the United States Food
and Drug Administration for the treatment of autism,
and these are for the associated behavioral disturbance
[4]. Although effective treatments, they are associated
with side-effects including sedation, cognitive impair-
ment, weight gain and metabolic disturbance [5].
I observed that patients with attention deficit hyper-
activity disorder (ADHD) who on their stimulant ther-
apy often still experienced persistent affective instability.
The addition of sodium valproate was undertaken in an
attempt to improve these symptoms. Unexpectedly, a
number of patients reported an improvement in their
ability to maintain eye contact during conversations,
which in turn enabled them to better read non-verbal
social cues and enhanced their comprehension andn Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bird Journal of Medical Case Reports 2015, 9:8 Page 2 of 5
http://www.jmedicalcasereports.com/content/9/1/8enjoyment of social interaction. Significantly, this benefi-
cial effect of sodium valproate appeared to have a narrow
therapeutic window, with the optimal range between 50
and 200mg daily. A complete loss of efficacy frequently
occurred above a dose of 400mg. Similarly, phenytoin is
an anti-epileptic that has shown to have some benefit in
the treatment of bipolar mood disorder [6].
I present a case of a man with a childhood diagnosis
of ASD and co-morbid ADHD with persistent disruptive
behavioral difficulties despite long-term treatment with
stimulant medication. Following the addition of a very
low dose of phenytoin there was an improvement in
multiple areas of his functioning, in particular in the
core areas of social interaction impaired in ASDs. He
was for the first time able to sustain eye contact, demon-
strated more spontaneous facial expression, and began
to use gestures during conversation. He also appeared to
enjoy and benefit from the company of others.
Evaluations of the effects of medication pre- and post-
treatment with phenytoin were two-fold: behavioral obser-
vations (for example, client and carer reports, clinician’s
observations) and formal ratings on behavioral scales (The
Depression Anxiety and Stress Scales (DASS) and The
Autism-Spectrum Quotient (AQ)).
The DASS is a 42-item self-administered questionnaire
designed to measure the magnitude of three negative
emotional states: depression, anxiety and stress [7]. This
instrument is considered to be an appropriate and reli-
able measure of overall improvement that may correlate
with overall functioning. Depression and anxiety are
among the most common ASD co-morbidities [8] and
correlate to significantly poorer life functioning [9].
The AQ, although not a diagnostic instrument, is use-
ful in identifying the extent of autistic traits shown by an
adult of normal intelligence. It was designed as a screen-
ing tool but also provides a quantitative approach to the
measurement of ASD symptoms and is considered to
have established test-retest reliability [10]. It was there-
fore useful in the assessment of clinical improvement.
Case presentation
My patient was a 19-year-old man diagnosed in early
childhood with ADHD and ASD. He was referred by his
local doctor for ongoing treatment as an adult. He had
experienced long-term difficulties in establishing and
maintaining lasting relationships and reading social cues.
His conversations were awkward and restricted to a nar-
row range of subjects and he was frequently impulsive
and insensitive during these interactions. These impair-
ments had contributed to his increasing social isolation
and conflict within the family environment. He had a
low threshold of irritation and intolerance of noise, light
and crowds. There was also a long history of outbursts
of anger, physical intimidation and frequent destructionto property at home. He was also disorganized, forgetful
and had difficulty completing tasks. He has always been
overactive, restless and impulsive. There was no history
of pervasive mood disturbance.Developmental and social history
There were early concerns about a potential develop-
mental delay and he was referred for a pediatric assess-
ment at age two years. He received speech therapy prior
to school and also repeated his pre-school year. Al-
though he was of average intellect, his significant and
specific learning, behavioral and communication difficul-
ties warranted a placement in a special education unit to
manage his needs. He experienced difficulties in both
reading and writing and he performed below all national
standards of literacy and numeracy. Reading remained
effortful and unrewarding, with difficulties focusing on
and reading along a line of text. At the age of seven he
had an occupational therapy assessment, which reported
difficulties with coordination, fine motor control, plan-
ning and sequencing. In the classroom he was reported
to be distracted and restless, presented with extreme
outbursts of anger and frequently ran away. He had poor
interpersonal skills, established few friendships, had odd
idiosyncratic language and repetitive hand flapping, and
had a history of being bullied.
He commenced stimulant medication during early
childhood and had trials of immediate-release dexam-
phetamine and methylphenidate with improvement in
classroom behavior. He had little interest or motivation
in taking his medication, resulting in generally poor ad-
herence. Without stimulant medication his behavior
quickly deteriorated.
Since leaving school he had obtained a number of part-
time unskilled jobs for eight to ten hours per week. He
was, however, unable to maintain them because of behav-
ioral and communication difficulties. He did not smoke
cigarettes or consume alcohol or illicit substances. There
was no significant family psychiatric history.
On presentation, he was taking methylphenidate
extended-release 72mg daily via an osmotic-controlled
release oral delivery system and melatonin 4mg every
night. He had been prescribed this medication for the
previous two years.Clinical assessment
During my clinical assessment, he was constantly rest-
less, appeared disinterested and was easily distracted. He
made little eye contact either when listening or speaking
and his non-verbal interaction was limited. His answers
to questions were minimal and his speech lacked normal
prosody. His blood pressure and pulse were within the
normal range although he was significantly overweight
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Following completion of his assessment an additional
dose of methylphenidate was recommended in the late
afternoon to try and reduce his frequent aggression at
this time. However, he stated that this suggestion was of
no interest to him and he did not care that others might
be upset by his behavior.
During the three months following his initial assess-
ment there was no alteration to his pharmacotherapy
and no improvement in his behavior. As a consequence
of his persistent social difficulties the option of a trial of
low-dose phenytoin was discussed. It was explained to
my patient and his mother that improvements in social
functioning had been observed by myself and been re-
ported by other patients who also had taken low-dose
phenytoin; although, these effects had not been demon-
strated outside the clinic nor was this an approved indi-
cation for the medication. My patient and his mother
signed a disclosure and informed consent document and
a trial of medication was organized for the following
consultation.
Two weeks later a sublingual test dose of approxi-
mately 2mg phenytoin was administered. Prior to this
dose my patient’s interaction reflected his usual behavior,
with little interest and social engagement. He was reluc-
tant to participate in conversation and his verbal re-
sponses were minimal and lacked elaboration; there was
only minimal facial expression, which appeared to be un-
connected to the content of his speech. Within 10 minutes
of taking the sublingual phenytoin he reported a reduction
in the effort required to contribute to conversation and
was able to sustain eye contact both when listening and
speaking. He was surprised about the effortless nature of
his eye gaze and also commented that he had never done
this before, and that previously he had always found it eas-
ier to avoid eye contact when speaking. He was now ex-
periencing the reverse, finding it harder to break away
from the mutual eye gaze. He stated he felt more relaxed
and was less distracted by other environmental visual and
sensory stimuli. His non-verbal interaction, demonstrated
by the raising of his eyebrows, smiling and nodding of his
head, appeared to be more spontaneous and natural.
During this assessment he read aloud two standardized
examples of a text, pre- and post-administration of the
phenytoin. He reported a reduction in the effort required
and improved comprehension and accuracy. He stated that
he was no longer as distracted by the other lines of text on
the page, which previously had resulted in becoming over-
whelmed and lost on the page. His speech was also more
fluid with more appropriate intonation. He denied any ad-
verse effects of the test dose. The following day he started
taking compounded 2mg phenytoin capsules in the morn-
ing in conjunction with his methylphenidate.After two weeks both he and his mother stated that his
communication with the family had improved and there
had been no aggressive outbursts. During the consultation
he was noticeably more engaged and appeared to enjoy
the interaction. His ability to maintain eye contact and his
non-verbal communication - facial expression, head
movements and posture -were more synchronized and
spontaneous.
Over the next four weeks he became inconsistent in
taking the phenytoin, and then ceased altogether. His
behavior reverted to the previous pattern of poor social
interaction; he became oppositional with outbursts of
anger and physical violence.
Nine months later he resumed taking the phenytoin,
this time as a single 4mg capsule in the morning. After
his first dose there was an improvement of his social be-
havior similar to his previous response, although there
was an apparent deterioration in the late afternoon. The
dose was increased from 4mg to 5mg and a larger cap-
sule formulated to try and prolong the release of the
phenytoin. This appeared to achieve a more consistent
improvement in behavior throughout the day, evident
both at home and at work. Increases in the dose above
5mg were not associated with any additional benefit. He
remained on the 5mg dose of phenytoin for over 18
months and reported that his work performance had
consistently improved sufficient to increase his working
hours and his level of responsibility. The violence and
destruction at home abated. His confidence improved
and for the first time he has established and sustained
peer-appropriate friendships.
His behavioral ratings prior to treatment with pheny-
toin and after seven months on the 5mg phenytoin are
presented in Figure 1. The manner in which my patient
endorsed the items on the AQ highlighted a reduction
of symptoms, with the most robust improvements in his
enjoyment of social occasions, ability to cope with chit
chat, and his preference to be with people rather than be
alone. His total AQ score dropped from 41 pre- to 27
post-treatment with phenytoin; a score of 32 or more is
considered to indicate clinically significant levels of aut-
istic traits [10]. Before treatment with phenytoin, his
DASS ratings recorded both depression and anxiety as
severe and stress as very severe. Post-treatment, there
was robust change in all domains, with an absence of de-
pressive symptoms and with both anxiety and stress be-
ing recorded as moderate.
Discussion
ASDs are characterized by social deficits and communi-
cation difficulties, and stereotyped or repetitive behav-
iors and interests. The social deficits have been noted in
autism as a failure to understand the intentions and
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Figure 1 Graphical presentation of behavioral ratings prior to and after seven months of continuous treatment with 5mg phenytoin.
DASS: Depression Anxiety Stress Scales (depression and anxiety clinically significant cut-off: 12; reliable change: 5 scale points; stress clinically significant
cut-off: 14; reliable change: 7 scale points); AQ: Autism-Spectrum Quotient (a score of 32 indicates clinically significant levels of autistic traits).
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with research data strong enough to obtain a rating of
‘established evidence’ [4] have been within the anti-
psychotic class and are for the treatment of the behav-
ioral manifestations of ASDs.
In this case report I have described the clinical presen-
tation of a patient with ASD who benefited clinically
with increased social functioning from treatment with
low-dose phenytoin. The initial sublingual test dose pro-
vided a more rapid onset of therapeutic effect compared
with the variable absorption often associated with oral
phenytoin [12], although the speed of response was con-
sistent with other pharmaceuticals agents [13]. The
medication was well tolerated and resulted in improve-
ments in multiple domains including the core social def-
icits associated with ASD. Perhaps the most significant
social change was my patient’s ability to establish and
maintain eye contact during conversation. This provided
an enhanced and more comfortable social engagement
and a sense of real-time feedback on the outcome of
conversation that previously had not occurred. His abil-
ity to sustain eye contact and interpret non-verbal com-
munication may have contributed to a reduction in
social anxiety and the improvement in quality of life re-
ported by my patient and his family.
This clinical case report provides potential evidence
that a low dose of a widely used anti-epileptic medica-
tion, phenytoin, may be capable of modifying the core
social cognitive deficits associated with ASDs. These
clinical improvements were reflected and maintained for
over seven months in the AQ and DASS.My previous clinical observations in similar patients
led to use of sub-therapeutic doses of an anti-epileptic
medication to improve social cognition. This discovery
was unexpected and I am unaware of prior similar scien-
tific reports. The pharmacological action of anti-epileptic
medication in ASD is not entirely unexpected because the
conditions may have a common neurodevelopment origin,
although a precise link between these two pathologies is
still undetermined [14]. The ability of a low dose of an
anti-epileptic medication to rescue autistic behavior in an
animal model has already been established. Dravet’s syn-
drome (DS) is a form of autism and epilepsy in which
there is a SCN1A mutation that encodes for VGSC type-1
(NaV1.1) [15], the primary sodium channel in the
GABAergic interneurons. An SCN1A haplo-insufficiency
results in a reduction of GABAergic transmission. Han
et al. reported that treatment with low-dose (1/40th of the
therapeutic dose) clonazepam, a positive allosteric modu-
lator of GABAA receptors, completely rescued the abnor-
mal social behaviors and deficits in fear memory in the
mouse model of DS, demonstrating that they are both
caused by impaired GABAergic function and sensitive to
very low (sub-therapeutic) doses of an anti-epileptic medi-
cation [16].
ASDs are increasingly thought to be characterized by a
disruption in the excitatory and inhibitory balance of
neural activity [17]. Mutations in genes involved in the
expression of excitatory and inhibitory neurotransmitters
(for example, glutamate and gamma-aminobutyric acid
(GABA)) have been identified in individuals with ASD
[18]. This has been supported by increasing evidence
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volve a GABA deficit [19]. More recently, strong evi-
dence has been building for a role of lesions in neuronal
voltage-gated sodium channel (VGSC) alpha subunits in
typical polygenic ASD [20]. These channels are also the
therapeutic targets of phenytoin in the brain [15,21].
The VGSC gene family comprises nine homologous
members, SCN1A to SCN11A, that encode the sodium-
selective ion channels NaV1.1 to NaV1.9. SCN1A,
SCN2A, SCN3A, SCN7A and SCN8A are associated with
ASD [20]. Whole-exome sequencing of nearly 1000 indi-
viduals identified SCN2A as the sole gene in which two
independent probands had non-sense variants that dis-
rupted the same gene, a highly significant result [22].
The importance of VGSCs in typical polygenic ASD was
also supported by a separate large sequencing study that
found de novo protein-altering mutations in the gene in
probands with ASD [23].
I hypothesize that, in a similar mechanism to the low-
dose clonazepam in this animal model of autism, low-dose
phenytoin may enhance GABA neurotransmission, thereby
correcting the imbalance between the GABAergic and
glutaminergic systems.Conclusions
While acknowledging this is an anecdotal single case
study, the absence of safe and effective treatments to ad-
dress the core deficits associated with ASD makes the im-
provements demonstrated with low-dose phenytoin in
this case noteworthy. The mechanism of action of low-
dose phenytoin is not known. However, I propose a hy-
pothesis to explain the therapeutic action based on our
current understanding ASD together with an associated
animal model. An independent placebo-controlled proof-
of-concept study of low-dose phenytoin will be required
to determine whether the clinical improvement demon-
strated in this case can be replicated in a larger cohort.Consent
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